PURE Bioscience, Inc. (NASDAQ: PURE ), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that recognized food industry experts Dave Pfanzelter and David Theno, Jr., Ph.D. have joined the Company’s Advisory Panel to provide guidance on issues ranging from marketing and branding to food safety and health regulations. Michael L. Krall, President and CEO of PURE Bioscience, stated, “The experience and leadership of Mr. Pfanzelter and Dr. Theno enhances and strengthens our approach to key market channels in food processing, food manufacturing and food service. We look forward to gaining their insight as we refine and implement our sales and growth strategy in this market.” Dave Pfanzelter said, “I believe that PURE’s SDC-based technology provides much-needed food safety solutions in an efficient and effective manner unlike anything currently available, and I am excited to work with PURE as we develop strategies to bring PURE’s products to market.” David Theno, Jr., Ph.D. added, “The industry is eager to implement enhanced safety measures to prevent food-borne illness associated with products, facilities, companies and brands, but traditional chemicals are not providing adequate protection. The broad-spectrum, quick and residual kills provided by PURE’s products can fortify even the strongest safety protocols and have the potential to improve food safety throughout the supply chain from farm-to-fork.” Mr. Pfanzelter was most recently senior vice president, Kellogg Company, president, Kellogg’s Specialty Channels and president, Kellogg Canada while also serving as part of the Kellogg Executive Committee and Global Leadership Team. Mr. Pfanzelter began his foodservice career in 1975 with Oscar Mayer Foods Corporation serving in several key sales and marketing positions, including director of marketing and national sales manager. In 1995, he was appointed vice president, sales of Kraft Foodservice, representing the combined manufactured brands of Oscar Mayer, General Foods and Kraft Foods. In 1998 Mr. Pfanzelter joined Keebler, serving as vice president and general manager of the food service division prior to Keebler’s acquisition by Kellogg in 2001.
Since 1998, Mr. Pfanzelter has been on the board of directors of Doctor’s Associates, the parent company of Subway Restaurants, the nation’s largest restaurant chain. In February 2012, Dave joined Wrigley Foods Advisory Board of Directors. He also served on the Board of the International Food Service Manufacturer’s Association as chairman and member of its executive committee.Dr. Theno is currently the chief executive officer of Gray Dog Partners, Inc., a technical consulting firm specializing in food safety and manufacturing, restaurant operations, supply chain management, strategic planning and facility design. Gray Dog Partners also provides consultation to federal, state and local regulatory bodies, including the U.S. Department of Agriculture (USDA), the U.S. Food and Drug Administration, the USDA’s Agricultural Marketing Service, and state and local health departments. Dr. Theno is widely respected in the food industry and is a frequent senior contributing editor for several trade journals as well as a keynote speaker for numerous national associations in the food industry. From 1993 to 2009, Dr. Theno served Jack in the Box Inc. as the corporate vice president – technical services, followed by his appointment as senior vice president and chief food safety officer. Prior to that, he spent six years as managing director and chief executive officer of Theno & Associates, a private contracting firm that supplied complete technical service resources to multiple facets of the food industry. Dr. Theno’s professional experience also includes executive positions in technical services and quality control at Foster Farms, Kellogg Company and Armour Food Company. Dr. Theno and Mr. Pfanzelter join food microbiology expert, Robert Deibel, Ph.D., on PURE’s Advisory Panel. Dr. Deibel joined the Advisory Panel in May 2011. About PURE Bioscience, Inc. PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements, the Company’s failure to implement or otherwise achieve the benefits of its strategic initiatives, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.